根除幽门螺杆菌对胃癌预防的效果:一项随机对照试验26.5年随访的更新报告
这项在中国南方高危地区开展的前瞻性随机安慰剂对照试验纳入1630例无症状幽门螺杆菌感染者,随机接受标准三联根除治疗(817例)或安慰剂(813例),随访至2020年12月(中位26.5年)。治疗组胃癌发病率低于安慰剂组(HR 0.57,95%CI 0.33-0.98),但在无癌前病变和无消化不良症状者中更明显;两组任何死亡终点均无统计学显著差异。
要点
- 根除幽门螺杆菌可降低高危人群胃癌发病率(HR 0.57,95%CI 0.33-0.98)。
- 无癌前病变者获益更明显(HR 0.37,95%CI 0.15-0.95)。
- 两组任何死亡终点均无统计学显著差异。
核心结论
- 根除幽门螺杆菌可能对高危人群提供长期胃癌保护,尤其在基线无癌前病变的感染者中。
研究设计与样本
- 前瞻性、随机、安慰剂对照试验,1994年7月在中国南方高危地区开展,纳入1630例无症状幽门螺杆菌感染者,随机接受标准三联根除治疗(817例)或安慰剂(813例),随访至2020年12月。
主要发现
- 26.5年随访期间,治疗组21例(2.57%)和安慰剂组35例(4.31%)诊断为胃癌,治疗组胃癌发病率低于安慰剂组(HR 0.57;95%CI 0.33-0.98)。
- 无癌前病变者中风险降低更明显(HR 0.37;95%CI 0.15-0.95),基线无消化不良症状者中亦更明显(HR 0.44;95%CI 0.21-0.94)。
- 安慰剂组持续感染527例中观察到32例胃癌,治疗组成功根除625例中仅16例(HR 0.46;95%CI 0.26-0.83)。
- 两组任何死亡终点均无统计学显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Helicobacter pylori infection is considered as the most important risk factor in the pathogenesis of gastric cancer. This study aims to evaluate the long-term effects of H pylori eradication treatment on the incidence and mortality of gastric cancer among a high-risk population. METHODS: This prospective, randomized, placebo-controlled trial was conducted in a high-risk area in southern China in July 1994. A total of 1630 asymptomatic, H pylori-infected individuals were randomly assigned to receive standard triple therapy for H pylori eradication (n = 817) or placebo (n = 813), and were followed up until December 2020. The primary outcome was incidence of gastric cancer. Total and cause-specific mortalities were the secondary outcomes. RESULTS: During 26.5 years of follow-up, 21 participants (2.57%) in the treatment arm and 35 (4.31%) in the placebo arm were diagnosed with gastric cancer. Participants receiving H pylori treatment had a lower incidence of gastric cancer compared with their placebo counterparts (hazard ratio [HR], 0.57; 95% CI, 0.33-0.98). More obvious risk reduction was observed among those without premalignant gastric lesions (HR, 0.37; 95% CI, 0.15-0.95) and those without dyspepsia symptoms at baseline (HR, 0.44; 95% CI, 0.21-0.94). Furthermore, compared with 32 cases of gastric cancer observed among 527 participants with persistent H pylori infection in the placebo group, only 16 were identified in 625 subjects with successful eradication in the treatment group (HR, 0.46; 95% CI, 0.26-0.83). However, there were no statistically significant differences for any mortality end points between the 2 groups. CONCLUSIONS: Eradication of H pylori might confer a long-term protection against gastric cancer in high-risk populations, especially for infected individuals without precancerous gastric lesions at baseline.
引用
- Yan L, Chen Y, Chen F, et al. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up. Gastroenterology. 2022. PMID: 35364066. doi:10.1053/j.gastro.2022.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。